ContraVir Pharmaceuticals (NASDAQ:CTRV) CRV431 data from an experimental model of hepatitis B virus (HBV) has been published in the peer-reviewed journal, PLOS ONE.
Denali Therapeutics (NASDAQ:DNLI) received FDA orphan drug designation and rare pediatric disease designation for DNL310 for the treatment of Hunter syndrome.
The FDA has cleared Ziopharm Oncology’s (NASDAQ:ZIOP) IND for its T-cell receptor therapy (TCR-T) for the treatment of solid tumors. Ziopharm’s TCR-T consists of T-cells that have been genetically modified to express...
Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) reported that a scientific paper entitled, “Human Translingual Neurostimulation Alters Resting Brain Activity in High-density EEG,” was published in the latest edition...
La Jolla Pharmaceutical (NASDAQ:LJPC) reported results from a pre-specified interim analysis of its Phase 2 study of LJPC-401 in patients with hereditary hemochromatosis (HH).
Axovant Gene Therapies (NASDAQ:AXGT) reported six-month data from its Phase 2 trial of AXO-Lenti-PD, a gene therapy for Parkinson’s disease (PD). AXO-Lenti-PD uses a single lentiviral vector to deliver three genes...
ContraVir Pharmaceuticals (NASDAQ:CTRV) reported that CRV431 significantly decreased the extent of fibrosis, or scarring of the liver, in a second animal model of liver fibrosis. CRV431 is a clinical stage cyclophilin...
Sierra Oncology (NASDAQ:SRRA) received FDA fast track designation for momelotinib for the treatment of myelofibrosis. Momelotinib is designed to improve anemia that frequently occurs in myelofibrosis, or cancer of the...
AnaptysBio (NASDAQ:ANAB) presented updated Phase 2a data of etokimab for the treatment of severe eosinophilic asthma at the European Academy of Allergy and Clinical Immunology congress. Etokimab is a humanized anti...
Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in a trial to compare once-daily versus twice-daily dosing of CTP-543 in alopecia areata patients. Alopecia areata is an autoimmune disease that causes partial...
Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) added three new clinics authorized to provide PoNS treatment in Canada, extending regional access to its innovative treatment.
Aimmune Therapeutics (NASDAQ:AIMT) reported new data from a Phase 3 study of AR101, which delivers a daily dose of peanut protein, as a treatment to reduce the frequency and severity of allergic reactions to peanuts...
ObsEva (NASDAQ:OBSV) completed patient recruitment for its Phase 3 trial of nolasiban for the improvement of rates of pregnancy and live birth in patients undergoing assisted reproduction technology or in-vitro...
Genocea Biosciences (NASDAQ:GNCA) presented positive Phase 1/2a data regarding its neoantigen vaccine candidate, GEN-009, at the American Society of Clinical Oncology annual meeting. GEN-009 is a personalized cancer...
Proteostasis Therapeutics’ (NASDAQ: PTI) PTI-428 has been granted orphan drug designation by the European Medicines Agency (EMA) for the treatment of cystic fibrosis (CF). CF is caused by a mutation in cystic fibrosis...
Verona Pharma (NASDAQ:VRNA) initiated a Phase 2 trial of its metered-dose inhaler (MDI) formulation of ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Ensifentrine inhibits...
Titan Pharmaceuticals (NASDAQ:TTNP) signed a pharmacy services agreement with Southside Specialty Pharmacy, further expanding access to treatment with Probuphine (buprenorphine) implant, Titan’s unique maintenance...
Zenabis Global (TSX:ZENA) received an industrial hemp production license from Health Canada. “This is the second cultivation license we have received from Health Canada this year, and is another important step...
Epizyme (NASDAQ:EPZM) submitted an NDA to the FDA for tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma. Epithelioid sarcoma is a very rare soft tissue sarcoma. Tazemetostat is a small...
REGENXBIO (NASDAQ:RGNX) has completed dosing in its Phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). RGX-314 uses REGENXBIO’s proprietary NAV gene delivery platform to...